

Special Issue

Molecular Research of Glioblastoma

Message from the Guest Editors

The molecular biology of human glioblastoma, the most aggressive primary brain tumor, is a fast-progressing field in which basic research needs to meet clinical expectations in terms of anti-tumor efficacy. Therefore, a deeper knowledge of the connection between the bio-molecular and clinical features of this disease is needed in order to develop new treatments. These include signal transduction pathways involved in glioma formation and progression, energy metabolism requirements, interactions between glioma cells and their microenvironment (immune cells, blood vessels, or neurons/gliial cells), as well as signaling mechanisms involved in these interactions. This Special Issue aims to present a collection of original research and review articles dealing with different aspects of the molecular biology and clinical features of glioblastoma, with the hope of shedding some light on the pathological mechanisms of this devastating tumor that may help to improve treatment strategies for patients with this disease.

Guest Editors

Dr. Esperanza R. Matarredona

Departamento de Fisiología, Facultad de Biología, Universidad de Sevilla, Seville, Spain

Dr. Ricardo Gargini

Neurooncology Unit, Instituto de Salud Carlos III-UFIEC, 28220 Madrid, Spain

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/76161

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).